secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2024-10-08T23:59:59+00:00
Accession:  0000950170-24-113410
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen reports favorable safety profile for PGN-EDO51 in Phase 2 DMD trial at WMS Congress
--------------------------------------------------------------------------------

- CONNECT1-EDO51 safety data as of Oct 3: no serious adverse events; all treatment-related AEs mild and resolved.
- One hypomagnesemia case resolved with oral supplementation; no discontinuations, dose interruptions or reductions.
- Presenting short oral and five posters on PGN-EDO51 (DMD) and PGN-EDODM1 (DM1) at WMS Congress in Prague Oct 8-12.
- Nonclinical data for both programs and FREEDOM-DM1 trial design also featured in poster sessions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000095017024113410/0000950170-24-113410-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000095017024113410/pepg-20241008.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-113410

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer